The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

The US regulator has set an action date of 26th September next year for a decision on KarXT, which combines muscarinic agonist xanomeline tartrate and muscarinic antagonist trospium chloride ...

KarXT combines xanomeline, a novel muscarinic M1/M4 agonist, with trospium, an already-approved muscarinic antagonist designed to reduce M1/M4-related side effects in the peripheral nervous system.

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...